G2GBIO

G2GBIO, Inc. was founded in March 2017, focusing on the development of sustained-release drugs for small molecule medications. Its name originates from its vision: "Innovative biologic therapies for global benefit." Lee stated that the company aims to enter the U.S. market, "the world's largest healthcare market." Currently, the company is conducting clinical trials for a sustained-release drug for Alzheimer’s disease and non-clinical trials for diabetes and continuous post-surgical pain treatment.